<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03730116</url>
  </required_header>
  <id_info>
    <org_study_id>IC4-05150-056-RUS</org_study_id>
    <nct_id>NCT03730116</nct_id>
  </id_info>
  <brief_title>Assessment of the Efficacy and Tolerability of the Fixed-dose Combination of Bisoprolol/Perindopril</brief_title>
  <acronym>STYLE</acronym>
  <official_title>Multicenter Observational Open Program. Assessment of the Efficacy and Tolerability of the Fixed-dose Combination of Bisoprolol/Perindopril in Patients With Arterial Hypertension and Stable CAD in Daily Clinical Practice (STYLE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Servier Russia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Servier Russia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study objective - to assess the efficacy, tolerability and adherence of&#xD;
      bisoprolol/perindopril FDC in patients with HT and stable CAD in everyday practice.&#xD;
&#xD;
      Type of the program: multicenter, observational, uncontrolled, open program. The program will&#xD;
      involve 480 general practitioners (GPs) and cardiologists from the primary care&#xD;
      facilities.Each doctor includes four patients. It is planned to include not less than 1920&#xD;
      patients in total.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicenter observational open program. Assessment of the efficacy and tolerability of the&#xD;
      fixed-dose combination of bisoprolol/perindopril in patients with arterial hypertension and&#xD;
      stable CAD in daily clinical practice (STYLE)&#xD;
&#xD;
      Study objectives and purposes:&#xD;
&#xD;
      Primary endpoints:&#xD;
&#xD;
        -  efficacy of bisoprolol/perindopril FDC in patients with HT and stable CAD in everyday&#xD;
           practice regarding the BP&#xD;
&#xD;
        -  efficacy of bisoprolol/perindopril FDC in patients with HT and stable CAD in everyday&#xD;
           practice regarding the angina&#xD;
&#xD;
      Secondary endpoints:&#xD;
&#xD;
        -  impact on the quality of life of bisoprolol/perindopril FDC in patients with HT and&#xD;
           stable CAD in everyday practice&#xD;
&#xD;
        -  adherence to bisoprolol/perindopril FDC therapy in patients with HT and stable CAD in&#xD;
           everyday practice The program will involve 480 general practitioners (GPs) and&#xD;
           cardiologists from the primary care facilities. Each doctor includes four patients. It&#xD;
           is planned to include not less than 1920 patients in total.&#xD;
&#xD;
      Milestones of the program:&#xD;
&#xD;
      FSI - November, 2018 LSLV- January, 2019 Database Lock - February, 2019 Statistic Report-&#xD;
      May, 2019 Clinical Study Report- January, 2020&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 14, 2018</start_date>
  <completion_date type="Actual">October 24, 2019</completion_date>
  <primary_completion_date type="Actual">October 24, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The Mean SBP Changes (mm Hg) at the Visit 3 vs. Baseline</measure>
    <time_frame>3 months</time_frame>
    <description>Changes in the mean office systolic BP levels (in mm Hg) in the sitting position</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of Bisoprolol/Perindopril FDC in Patients With HT and Stable CAD in Everyday Practice Regarding the BP: % of Patients Achieving Target Levels</measure>
    <time_frame>3 month</time_frame>
    <description>The percentage of the patients achieved the target levels of clinical BP among included patients ( SBP &lt; 140 mm Hg and DBP &lt; 90 mm Hg) with HT and stable CAD recieving Bisoprolol/Perindopril FDC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of Bisoprolol/Perindopril FDC in Patients With HT and Stable CAD in Everyday Practice: # of Angina Attacks</measure>
    <time_frame>3 month</time_frame>
    <description>Average decrease of the number of angina attacks in patients with HT and stable CAD who recieved the bisoprolol/perindopril FDC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in the Mean Office Diastolic BP Levels (in mm Hg) in the Sitting Position</measure>
    <time_frame>3 months</time_frame>
    <description>Changes in the mean office diastolic BP levels (in mm Hg) in the sitting position among the patints with HT and CAD recieving bis/perindopril FDC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact on the Quality of Life of Bisoprolol/Perindopril FDC in Patients With HT and Stable CAD in Everyday Practice: VAS</measure>
    <time_frame>3 month</time_frame>
    <description>Changes of the score in the visual analog scale (VAS) to assess the wellbeing; (minimum score 0 mm and maximum score 100 mm) among patients with HT and CAD recieving biso/perindopril FDC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Good and Moderate Adherence to Bisoprolol/Perindopril FDC Therapy in Patients With HT and Stable CAD in Everyday Practice</measure>
    <time_frame>3 month</time_frame>
    <description>Percentage of the patients with definite answer on question from questionnaire regarding adherence; (Compliance evaluation test - 6 questions tes; Answer &quot;No&quot; to all questions: good compliance; Answer &quot;Yes&quot; to 1-2 questions: minor compliance; Answer &quot;Yes&quot; to 3 or more questions: noncompliance)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1909</enrollment>
  <condition>Arterial Hypertension</condition>
  <condition>CHD - Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>the patients with HT and concomitant stable CAD</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bisoprolol/perindopril FDC</intervention_name>
    <description>the first and only single-pill combination of beta-blocker and ACE inhibitor</description>
    <arm_group_label>the patients with HT and concomitant stable CAD</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        It is planned to include into the program the patients with HT and concomitant stable CAD.&#xD;
        It is planned to include not less than 1920 patients in total.&#xD;
&#xD;
        The patient is included in the program, if the doctor decides to prescribe FDC with&#xD;
        beta-blocker bisoprolol and ACE inhibitor perindopril in accordance to the instruction for&#xD;
        use.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Stable CAD, defined as stable angina pectoris of class 1-3 by CCS (Canadian&#xD;
             Cardiovascular Society) classification;&#xD;
&#xD;
          -  Previously or newly diagnosed essential hypertension&#xD;
&#xD;
          -  Age 18 to 79 years old;&#xD;
&#xD;
          -  Informed consent of the patient for participation in the program;&#xD;
&#xD;
          -  Decision of the doctor to prescribe bisoprolol/perindopril FDC before the inclusion in&#xD;
             the program in accordance to the instruction for use.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Stable angina pectoris, class 4;&#xD;
&#xD;
          -  History of myocardial infarction or cerebrovascular event within the past 3 months;&#xD;
&#xD;
          -  Unstable angina within the past 6 months;&#xD;
&#xD;
          -  Chronic heart failure classes 3-4 (NYHA);&#xD;
&#xD;
          -  Type 1 diabetes mellitus or decompensated type 2 diabetes mellitus;&#xD;
&#xD;
          -  Any serious decompensated concomitant diseases requiring the regular medical therapy;&#xD;
&#xD;
          -  Inability to understand the essence of the program and follow the recommendations;&#xD;
&#xD;
          -  Contraindications to beta-blockers or ACE inhibitors using;&#xD;
&#xD;
          -  Participation of the patient in other trials in the present time or within 30 days&#xD;
             before the start of observational program.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergei Boytsov</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>FSBI NMIC of Cardiology of the Ministry of Health of Russia</name>
      <address>
        <city>Moscow</city>
        <zip>121552</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 22, 2018</study_first_submitted>
  <study_first_submitted_qc>November 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2018</study_first_posted>
  <results_first_submitted>June 19, 2020</results_first_submitted>
  <results_first_submitted_qc>November 27, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 23, 2020</results_first_posted>
  <last_update_submitted>December 23, 2020</last_update_submitted>
  <last_update_submitted_qc>December 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bisoprolol</mesh_term>
    <mesh_term>Perindopril</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The sponsor reserves the exclusive right to all materials, information, unpublished documentation, results and information obtained during the research. The Sponsor reserves the right to send research data to the health authorities (individual registration cards, analysis results, reports).&#xD;
No unpublished documentation or information transmitted to researchers can be transferred to unauthorized persons without the prior written consent of Sponsor.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 8, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/16/NCT03730116/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 8, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/16/NCT03730116/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>the Patients With HT and Concomitant Stable CAD</title>
          <description>Observational study - 1 group - bisoprolol/perindopril FDC: single-pill combination of beta-blocker and ACE inhibitor</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Inclusion</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1909">Planned to include 1920 pts, included 1909</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>FVFP</title>
              <participants_list>
                <participants group_id="P1" count="1909"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1909"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>1 Month After Inclusion</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1909"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>1 Month After Inclusion</title>
              <participants_list>
                <participants group_id="P1" count="1909"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1909"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>3 Month After Inclusion</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1909"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>3 Month After Inclusion</title>
              <participants_list>
                <participants group_id="P1" count="1909"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1892"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>1909 patients were included however 17 were excluded from the population analysed due to violation of inclusion creteria. Therefore full analysis set is 1892.</population>
      <group_list>
        <group group_id="B1">
          <title>the Patients With HT and Concomitant Stable CAD</title>
          <description>Observational study - 1 group - bisoprolol/perindopril FDC: single-pill combination of beta-blocker and ACE inhibitor</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1892"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>patients with arterial hypertension and stable coronary heart disease</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1892"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1192"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>- in 11 participants no gender indicated</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1881"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1007"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="874"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Russia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1892"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1909"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Mean SBP Changes (mm Hg) at the Visit 3 vs. Baseline</title>
        <description>Changes in the mean office systolic BP levels (in mm Hg) in the sitting position</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mean of SBP Changes</title>
            <description>Changes in the mean office systolic BP levels (in mm Hg) in the sitting position among the patients with HT and CAD recieved the biso/perindopril FDC</description>
          </group>
        </group_list>
        <measure>
          <title>The Mean SBP Changes (mm Hg) at the Visit 3 vs. Baseline</title>
          <description>Changes in the mean office systolic BP levels (in mm Hg) in the sitting position</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1892"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.5" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of Bisoprolol/Perindopril FDC in Patients With HT and Stable CAD in Everyday Practice Regarding the BP: % of Patients Achieving Target Levels</title>
        <description>The percentage of the patients achieved the target levels of clinical BP among included patients ( SBP &lt; 140 mm Hg and DBP &lt; 90 mm Hg) with HT and stable CAD recieving Bisoprolol/Perindopril FDC</description>
        <time_frame>3 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>the Patients With HT and Concomitant Stable CAD</title>
            <description>Observational study - 1 group - bisoprolol/perindopril FDC: single-pill combination of beta-blocker and ACE inhibitor&#xD;
All patients included in the study received a FDC of beta-blocker bisoprolol and ACE inhibitor perindopril. In accordance with the investigation schedule, during the study the investigators collected subjective data from patients on the treatment compliance and tolerability (complaints), performed physical and instrumental examinations, as well as collected data from patients regarding the number of angina attacks and consumption of short-acting nitrates, adverse events/reactions, and assessed their quality of life using the visual analogue scale (VAS).</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Bisoprolol/Perindopril FDC in Patients With HT and Stable CAD in Everyday Practice Regarding the BP: % of Patients Achieving Target Levels</title>
          <description>The percentage of the patients achieved the target levels of clinical BP among included patients ( SBP &lt; 140 mm Hg and DBP &lt; 90 mm Hg) with HT and stable CAD recieving Bisoprolol/Perindopril FDC</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1892"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1640"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of Bisoprolol/Perindopril FDC in Patients With HT and Stable CAD in Everyday Practice: # of Angina Attacks</title>
        <description>Average decrease of the number of angina attacks in patients with HT and stable CAD who recieved the bisoprolol/perindopril FDC</description>
        <time_frame>3 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>the Patients With HT and Concomitant Stable CAD</title>
            <description>the patients with HT and concomitant stable CAD recieved bisoprolol/perindopril FDC</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Bisoprolol/Perindopril FDC in Patients With HT and Stable CAD in Everyday Practice: # of Angina Attacks</title>
          <description>Average decrease of the number of angina attacks in patients with HT and stable CAD who recieved the bisoprolol/perindopril FDC</description>
          <units>number of angina attacks per week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1892"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in the Mean Office Diastolic BP Levels (in mm Hg) in the Sitting Position</title>
        <description>Changes in the mean office diastolic BP levels (in mm Hg) in the sitting position among the patints with HT and CAD recieving bis/perindopril FDC</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mean Office DBP Changes Between v3 vs Baseline</title>
            <description>mean office DBP changes between v3 vs baseline among patients with HT and CAD recieving biso/perindopril FDC</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Mean Office Diastolic BP Levels (in mm Hg) in the Sitting Position</title>
          <description>Changes in the mean office diastolic BP levels (in mm Hg) in the sitting position among the patints with HT and CAD recieving bis/perindopril FDC</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1892"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Impact on the Quality of Life of Bisoprolol/Perindopril FDC in Patients With HT and Stable CAD in Everyday Practice: VAS</title>
        <description>Changes of the score in the visual analog scale (VAS) to assess the wellbeing; (minimum score 0 mm and maximum score 100 mm) among patients with HT and CAD recieving biso/perindopril FDC</description>
        <time_frame>3 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>the Patients With HT and Concomitant Stable CAD</title>
            <description>Observational study - 1 group - bisoprolol/perindopril FDC: single-pill combination of beta-blocker and ACE inhibitor</description>
          </group>
        </group_list>
        <measure>
          <title>Impact on the Quality of Life of Bisoprolol/Perindopril FDC in Patients With HT and Stable CAD in Everyday Practice: VAS</title>
          <description>Changes of the score in the visual analog scale (VAS) to assess the wellbeing; (minimum score 0 mm and maximum score 100 mm) among patients with HT and CAD recieving biso/perindopril FDC</description>
          <units>units on a scale - mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1892"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.1" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Good and Moderate Adherence to Bisoprolol/Perindopril FDC Therapy in Patients With HT and Stable CAD in Everyday Practice</title>
        <description>Percentage of the patients with definite answer on question from questionnaire regarding adherence; (Compliance evaluation test - 6 questions tes; Answer &quot;No&quot; to all questions: good compliance; Answer &quot;Yes&quot; to 1-2 questions: minor compliance; Answer &quot;Yes&quot; to 3 or more questions: noncompliance)</description>
        <time_frame>3 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>the Patients With HT and Concomitant Stable CAD</title>
            <description>Observational study - 1 group - bisoprolol/perindopril FDC: single-pill combination of beta-blocker and ACE inhibitor</description>
          </group>
        </group_list>
        <measure>
          <title>Good and Moderate Adherence to Bisoprolol/Perindopril FDC Therapy in Patients With HT and Stable CAD in Everyday Practice</title>
          <description>Percentage of the patients with definite answer on question from questionnaire regarding adherence; (Compliance evaluation test - 6 questions tes; Answer &quot;No&quot; to all questions: good compliance; Answer &quot;Yes&quot; to 1-2 questions: minor compliance; Answer &quot;Yes&quot; to 3 or more questions: noncompliance)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1892"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1827"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 month</time_frame>
      <desc>Were registered 9 AEs in 4 patients, of which 3 patients had adverse drug reactions resulting in the withdrawal from treatment. 1 patient started to take the study drug periodically and not daily, which did not comply with the instructions for the medical use of the drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>the Patients With HT and Concomitant Stable CAD</title>
          <description>Observational study - 1 group - bisoprolol/perindopril FDC: single-pill combination of beta-blocker and ACE inhibitor</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1909"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1909"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension with dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1909"/>
              </event>
              <event>
                <sub_title>bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1909"/>
              </event>
              <event>
                <sub_title>syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1909"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Non-traumatic vertebral compression fracture that required hospitalization</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1909"/>
              </event>
              <event>
                <sub_title>death of unknown caus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1909"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1909"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1909"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>A special situation: use of the drug not daily, but as needed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1909"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry cough and tingling throat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1909"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mrdical manager - Yuriy Burtsev</name_or_title>
      <organization>Sevier</organization>
      <phone>8-495-93707-00 ext 1389</phone>
      <email>Yuriy.Burtsev@servier.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

